Arnauld Fiogbé

Dr. Arnauld Fiogbé

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2018 in Clinical Infectious Diseases
Verified
Journal Article
Open access
MPMarta Di Pasquale
Marta Di Pasquale
GSGiovanni Sotgiu
Giovanni Sotgiu
AGAndrea Gramegna
Andrea Gramegna
DRDejan Radovanovic
Dejan Radovanovic
STSilvia Terraneo
Silvia Terraneo
LLLucía Labra
Lucía Labra
Background: The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods: We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results: At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non–community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001). Conclusions: Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

1 December 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
SAStefano Aliberti
Stefano Aliberti
LRLuis F Reyes
Luis F Reyes
Paola FaverioPaola Faverio
Paola Faverio
GSGiovanni Sotgiu
Giovanni Sotgiu
SDSimone Dore
Simone Dore
LLLucía Labra
Lucía Labra

1 February 2019 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
AFArnauld Fiogbé
Arnauld Fiogbé
GAG. Agodokpessi
G. Agodokpessi
JTJ. F. Tessier
J. F. Tessier
DAD. Affolabi
D. Affolabi
DZD. M. Zannou
D. M. Zannou
OMO. Marcy
O. Marcy
SETTING: National teaching hospital for the management of respiratory diseases, Cotonou, Benin. OBJECTIVE: 1) To estimate the prevalence of lung function impairment (LFI) and associated factors in patients cured of pulmonary tuberculosis (PTB); and 2) to determine the link between human immunodeficiency virus (HIV) infection and LFI occurrence. DESIGN: We performed a cross-sectional study in cured patients with smear-positive TB (PTB+) treated between 2012 and 2015. We recruited two control groups of 70 HIV-infected (HIV+/TB–) and 70 HIV-negative participants without TB (HIV–/TB–). We performed spirometry in all participants to identify LFI (obstructive, restrictive or mixed) and the 6-min walk test (6-MWT) in PTB+ participants. We assessed the factors associated with LFI using logistic regression. RESULTS: Of 4711 subjects with PTB, 241 were contacted and 189 were included. The median age was 37 years; 128 (68.0%) were male. Overall, 85 cured PTB+ patients had LFI (45.0%). Extent of initial radiological lesions, time between symptom onset and treatment, and female sex were independently associated with LFI. Fifty-five (29.1%) cured PTB+ patients had an abnormal 6-MWT; those with LFI had a higher risk of poor exercise tolerance (OR 2.23; interquartile range 1.16–4.30). We did not find any association between HIV infection and LFI. CONCLUSION: LFI is very common in cured PTB+ patients from Benin and significantly impacts exercise tolerance.

1 February 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
KPKaren Du Preez
Karen Du Preez
BGBetina Mendez Alcântara Gabardo
Betina Mendez Alcântara Gabardo
SKSushil Kumar Kabra
Sushil Kumar Kabra
RTRina Triasih
Rina Triasih
TLTrisasi Lestari
Trisasi Lestari
Steve GrahamSteve Graham
Steve Graham
Over the past 15 years, and despite many difficulties, significant progress has been made to advance child and adolescent tuberculosis (TB) care. Despite increasing availability of safe and effective treatment and prevention options, TB remains a global health priority as a major cause of child and adolescent morbidity and mortality—over one and a half million children and adolescents develop TB each year. A history of the global public health perspective on child and adolescent TB is followed by 12 narratives detailing challenges and progress in 19 TB endemic low and middle-income countries. Overarching challenges include: under-detection and under-reporting of child and adolescent TB; poor implementation and reporting of contact investigation and TB preventive treatment services; the need for health systems strengthening to deliver effective, decentralized services; and lack of integration between TB programs and child health services. The COVID-19 pandemic has had a significant negative impact on case detection and treatment outcomes. Child and adolescent TB working groups can address country-specific challenges to close the policy–practice gaps by developing and supporting decentral ized models of care, strengthening clinical and laboratory diagnosis, including of multidrug-resistant TB, providing recommended options for treatment of disease and infection, and forging strong collaborations across relevant health sectors.

8 July 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
VSVéronique Suttels
Véronique Suttels
JTJacques D Du Toit
Jacques D Du Toit
AFArnauld Fiogbé
Arnauld Fiogbé
AWAblo Prudence Wachinou
Ablo Prudence Wachinou
BGBrice Guendehou
Brice Guendehou
MHMary Anne Hartley
Mary Anne Hartley
Point-of-care ultrasound (POCUS) is an increasingly accessible skill, allowing for the decentralization of its use to nonspecialist healthcare workers to guide routine clinical decision-making. The advent of ultrasound-on-a-chip has transformed the technology into a portable mobile health device. Because of its high sensitivity to detect small consolidations, pleural effusions, and subpleural nodules, POCUS has recently been proposed as a sputum-free likely triage tool for tuberculosis (TB). To make an objective assessment of the potential and limitations of POCUS in routine TB management, we present a Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis based on a review of the relevant literature and focusing on Sub-Saharan Africa (SSA). We identified numerous strengths and opportunities of POCUS for TB management, e.g., accessible, affordable, easy to use and maintain, expedited diagnosis, extrapulmonary TB detection, safer pleural/pericardial puncture, use in children/pregnant women/people living with HIV, targeted screening of TB contacts, monitoring TB sequelae, and creating artificial intelligence decision support. Weaknesses and external threats such as operator dependency, lack of visualization of central lung pathology, poor specificity, lack of impact assessments and data from SSA must be taken into consideration to ensure that the potential of the technology can be fully realized in research as in practice.

8 April 2022 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
AWAblo Prudence Wachinou
Ablo Prudence Wachinou
CHCorinne Houehanou
Corinne Houehanou
SASerge Ade
Serge Ade
TTTerence Totah
Terence Totah
MBMathieu Berger
Mathieu Berger
RHRaphael Heinzer
Raphael Heinzer